Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
ATRC-101 for Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing ATRC-101, an antibody derived from a naturally occurring human antibody, for safety, tolerability, PK, and biological activity when administered every 2 weeks or every 3 weeks as a monotherapy or in combination with other anticancer agents.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.